InnoCare Pharma Limited (OTCMKTS:INCPF) Short Interest Update

InnoCare Pharma Limited (OTCMKTS:INCPF) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totaling 215,000 shares, a growth of 73.4% from the August 15th total of 124,000 shares. Based on an average daily volume of 0 shares, the short-interest ratio is currently ∞ days.

InnoCare Pharma Stock Performance

Shares of INCPF remained flat at $1.55 during mid-day trading on Thursday. The firm’s 50-day simple moving average is $1.55 and its two-hundred day simple moving average is $1.55. InnoCare Pharma has a twelve month low of $1.55 and a twelve month high of $2.31.

Analyst Ratings Changes

Separately, Morgan Stanley raised shares of InnoCare Pharma to an “overweight” rating in a research note on Thursday, May 28th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy”.

InnoCare Pharma Company Profile

InnoCare Pharma Ltd is a China-based, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule targeted therapies for oncology. Headquartered in Shenzhen, Guangdong Province, the company leverages structure-based drug design and comprehensive preclinical screening to advance drug candidates that address high-unmet-need cancers.

The company’s development pipeline comprises multiple small-molecule inhibitors in various stages of preclinical and early clinical evaluation.